Streetbeat News

Products Services

AZN

The National Medical Products Administration of China has approved AstraZeneca's Soliris (eculizumab) for Neuromyelitis Optica Spectrum Disorder in patients with anti-aquaporin-4 antibody positive.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 8:49 am

AAPL

MSFT

SFTBF

OpenAI CEO Sam Altman has denied rumors of working on the 'iPhone of AI', a relief to Apple Inc. Altman confirmed that he, along with former Apple designer Sir Jony Ive and SoftBank's Masayoshi Son, is working on a consumer-centric device, but it will not compete with smartphones. Microsoft, one of the largest shareholders of OpenAI, will also contribute to the project.

Portfolio Pulse from Rounak Jain

October 18, 2023 | 8:00 am

AAPL

Apple Inc. (NASDAQ:AAPL) is facing display issues with its Watch Series 9 and Ultra 2, including flickering screens and pink complications. The company is reportedly working on a fix with the upcoming watchOS 10.1 update. The issues have been reported across all current public versions of watchOS 10. Apple has not yet made a public statement addressing the issue or specifying a release date for the watchOS 10.1 update.

Portfolio Pulse from Ananya Gairola

October 18, 2023 | 7:33 am

GSK

PFE

ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK) and Pfizer (PFE), is set to present 23 abstracts from its HIV treatment and prevention portfolio at the EACS 2023. The presentation will include long-term and real-world data from ViiV Healthcare's portfolio of medicines, including long-acting and 2-drug regimens.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 7:32 am

TSLA

Tesla Inc. (NASDAQ:TSLA) has not released an Autopilot safety data report in a year, leading to concerns about the company's transparency. The company had been publishing a quarterly report on Autopilot safety since 2018, but this practice stopped without explanation. The lack of data makes it difficult to track improvements over time, raising questions about Tesla's commitment to deliver on promises made to new buyers since 2016.

Portfolio Pulse from Benzinga Neuro

October 18, 2023 | 7:27 am

GILD

Gilead Sciences, Inc. (NASDAQ:GILD) has announced the first Phase 2 clinical trial in Europe, PURPOSE 5, to evaluate an investigational long-acting HIV prevention option. The study will compare the use of lenacapavir with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The trial will focus on recruiting participants from groups in France and the UK that are disproportionally affected by HIV and often underrepresented in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 7:12 am

RHHBF

RHHBY

RHHVF

Roche's Genentech announced results from the primary analysis of the Phase III ALINA study. The data showed an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC). This is significant as about half of people with early-stage NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy. The data will be presented during an ESMO 2023 Presidential Symposium.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 7:04 am

FXCOF

NVDA

NVIDIA has partnered with Foxconn to drive the AI industrial revolution with new factories and systems. The partnership aims to leverage NVIDIA's AI and computing capabilities with Foxconn's manufacturing expertise.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 7:02 am

TAK

Takeda Pharmaceutical Company Limited (TAK) announced the topline results of its Phase 3 ADMIRE-CD II trial of Alofisel in complex Crohn's perianal fistulas. The detailed results and data analysis are yet to be released.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 6:55 am

WDS

Woodside Energy reported 3Q23 revenue of $3.269B, down 44% YoY but up 6% sequentially. The company delivered quarterly production of 47.8 MMboe (520 Mboe/day), up 8% sequentially. Sales volume was up 10% from Q2 2023, primarily due to higher production. The company also achieved first production at Shenzi North in September 2023, ahead of the 2024 target.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 6:45 am